Sir, Approximately 10-25% of the causes of gynecomastia are drug-induced. [1] Gynecomastia may result from imbalance in levels of androgen and estrogen as well as the elevated level of prolactin. [2] Drugs involving these hormone systems are likely to cause gynecomastia. Antipsychotic medications-induced hyperprolactinemia may manifest as gynecomastia. [3] Antipsychotic medications such as clozapine, olanzapine, aripiprazole, ziprasidone, and quetiapine possess prolactin-sparing property, hence the risk of gynecomastia with these medications is low. [3] [4] [5] The evidence for olanzapine-induced gynecomastia are scarce and limited to case reports.
A 20-year-old male had complaints of suspiciousness, fearfulness, increased physical activity, and decreased sleep for the last 1 week. These symptoms caused significant impairment in day to day functioning. This was the first episode of psychiatric illness. Physical examination of the patient did not reveal any abnormality. His routine blood investigations, thyroid function tests were within normal limits. He was diagnosed with acute and transient psychotic disorder and was started on olanzapine 10 mg/day and clonazepam 0.5 mg/day. The patient had shown improvement on the above treatment and his symptoms resolved completely in a month time. At 6 months follow-up visit, the patient reported painful enlargement of both breasts. The enlargement was asymmetrical; more in the left side than right. The patient did not report any other side effects commonly observed with olanzapine. The dose of olanzapine was reduced to 5 mg/day as the patient was clinical stable and acetaminophen 500 mg was prescribed for pain on as and when required. After 2 months of dose reduction, there was a significant improvement. The tenderness as well as enlargement of both breasts resolved completely. Causality assessment had been done using Naranjo adverse drug reaction probability scale which was suggestive of "probable adverse drug reaction" to olanzapine.
Our patient had reported asymmetric, tender enlargement of the breasts (gynecomastia was more evident in left side than right). However, there was no sexual dysfunction. The side effect was reported with 10 mg/day olanzapine which improved when the dose of medication was reduced to 5 mg/day. There is evidence of unilateral gynecomastia with antipsychotic risperidone in a case study by Mendhekar and Andrade; [6] however, similar evidence are lacking for olanzapine.
Some evidence also suggest that switching to olanzapine from risperidone improves the treatment-emergent prolactin disturbance and the improvement remains sustained over time. [7] Dopamine and prolactin have antagonistic action with each other. Antipsychotic medications elevate prolactin levels through dopamine blockade. Dopamine blockade is also responsible for the efficacy of antipsychotic medications. It is required to observe whether side effects associated with hyperprolactinemia could predict the response to antipsychotics.
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Sir, Few studies have examined gender differences in persistent delusional disorder (PDD), which itself are under researched. Available literature suggests that PDD is slightly more predominant in females, who tend to have a later age at the onset of illness. Females have also been found to have better treatment response as compared to males, perhaps due to better adherence and treatment-seeking behavior. [1] [2] [3] Some studies have reported erotomanic delusions as being more common in females. Others have reported that persecution is the most common theme of delusions among both males and females, with no gender differences in the content of delusions or comorbid depression. [4] Substance dependence is reportedly more common among males with PDD. [2] We examined gender differences in PDD at a tertiary care center in India. Ethical clearance for the study was obtained from the Institute Ethics Committee. We reviewed the case records of 455 patients with PDD (males: n = 236 [51.9%]; females: n = 219 [48.1%]) as part of a retrospective review published earlier. [5] We examined gender differences on age, sociodemographics, illness variables including age at the onset of illness, duration of illness, family history, clinical and treatment details, occupational functioning, number of follow-ups,
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